207 related articles for article (PubMed ID: 18326583)
1. Topological mapping of the asymmetric drug binding to the human ether-à-go-go-related gene product (HERG) potassium channel by use of tandem dimers.
Myokai T; Ryu S; Shimizu H; Oiki S
Mol Pharmacol; 2008 Jun; 73(6):1643-51. PubMed ID: 18326583
[TBL] [Abstract][Full Text] [Related]
2. Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach.
Imai YN; Ryu S; Oiki S
J Med Chem; 2009 Mar; 52(6):1630-8. PubMed ID: 19260734
[TBL] [Abstract][Full Text] [Related]
3. Refining insights into high-affinity drug binding to the human ether-à-go-go-related gene potassium channel.
Hancox JC; James AF
Mol Pharmacol; 2008 Jun; 73(6):1592-5. PubMed ID: 18381562
[TBL] [Abstract][Full Text] [Related]
4. Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels.
Perrin MJ; Kuchel PW; Campbell TJ; Vandenberg JI
Mol Pharmacol; 2008 Nov; 74(5):1443-52. PubMed ID: 18701618
[TBL] [Abstract][Full Text] [Related]
5. Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domain.
Duan JJ; Ma JH; Zhang PH; Wang XP; Zou AR; Tu DN
Acta Pharmacol Sin; 2007 Jul; 28(7):959-67. PubMed ID: 17588331
[TBL] [Abstract][Full Text] [Related]
6. Block of hERG channel by ziprasidone: biophysical properties and molecular determinants.
Su Z; Chen J; Martin RL; McDermott JS; Cox BF; Gopalakrishnan M; Gintant GA
Biochem Pharmacol; 2006 Jan; 71(3):278-86. PubMed ID: 16325148
[TBL] [Abstract][Full Text] [Related]
7. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
Zachariae U; Giordanetto F; Leach AG
J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
[TBL] [Abstract][Full Text] [Related]
8. In vitro modulation of HERG channels by organochlorine solvent trichlormethane as potential explanation for proarrhythmic effects of chloroform.
Scholz EP; Alter M; Zitron E; Kiesecker C; Kathöfer S; Thomas D; Kreye VA; Kreuzer J; Becker R; Katus HA; Greten J; Karle CA
Toxicol Lett; 2006 Aug; 165(2):156-66. PubMed ID: 16647228
[TBL] [Abstract][Full Text] [Related]
9. 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.
Gordon E; Lozinskaya IM; Lin Z; Semus SF; Blaney FE; Willette RN; Xu X
Mol Pharmacol; 2008 Mar; 73(3):639-51. PubMed ID: 18042732
[TBL] [Abstract][Full Text] [Related]
10. Molecular determinants of cocaine block of human ether-á-go-go-related gene potassium channels.
Guo J; Gang H; Zhang S
J Pharmacol Exp Ther; 2006 May; 317(2):865-74. PubMed ID: 16397089
[TBL] [Abstract][Full Text] [Related]
11. [HERG K+ channel, the target of anti-arrhythmias drugs].
Guan FY; Yang SJ
Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
[TBL] [Abstract][Full Text] [Related]
12. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
Wang L; Wible BA; Wan X; Ficker E
J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
[TBL] [Abstract][Full Text] [Related]
13. The membrane permeable calcium chelator BAPTA-AM directly blocks human ether a-go-go-related gene potassium channels stably expressed in HEK 293 cells.
Tang Q; Jin MW; Xiang JZ; Dong MQ; Sun HY; Lau CP; Li GR
Biochem Pharmacol; 2007 Dec; 74(11):1596-607. PubMed ID: 17826747
[TBL] [Abstract][Full Text] [Related]
14. APETx1 from sea anemone Anthopleura elegantissima is a gating modifier peptide toxin of the human ether-a-go-go- related potassium channel.
Zhang M; Liu XS; Diochot S; Lazdunski M; Tseng GN
Mol Pharmacol; 2007 Aug; 72(2):259-68. PubMed ID: 17473056
[TBL] [Abstract][Full Text] [Related]
15. Molecular determinants of hERG channel block by terfenadine and cisapride.
Kamiya K; Niwa R; Morishima M; Honjo H; Sanguinetti MC
J Pharmacol Sci; 2008 Nov; 108(3):301-7. PubMed ID: 18987434
[TBL] [Abstract][Full Text] [Related]
16. Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.
Karczewski J; Wang J; Kane SA; Kiss L; Koblan KS; Culberson JC; Spencer RH
Biochem Pharmacol; 2009 May; 77(10):1602-11. PubMed ID: 19426697
[TBL] [Abstract][Full Text] [Related]
17. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
Durdagi S; Duff HJ; Noskov SY
J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
[TBL] [Abstract][Full Text] [Related]
18. Interaction simulation of hERG K+ channel with its specific BeKm-1 peptide: insights into the selectivity of molecular recognition.
Yi H; Cao Z; Yin S; Dai C; Wu Y; Li W
J Proteome Res; 2007 Feb; 6(2):611-20. PubMed ID: 17269718
[TBL] [Abstract][Full Text] [Related]
19. Block of the hERG channel by bupivacaine: Electrophysiological and modeling insights towards stereochemical optimization.
Sintra Grilo L; Carrupt PA; Abriel H; Daina A
Eur J Med Chem; 2011 Aug; 46(8):3486-98. PubMed ID: 21624711
[TBL] [Abstract][Full Text] [Related]
20. Effect of S5P alpha-helix charge mutants on inactivation of hERG K+ channels.
Clarke CE; Hill AP; Zhao J; Kondo M; Subbiah RN; Campbell TJ; Vandenberg JI
J Physiol; 2006 Jun; 573(Pt 2):291-304. PubMed ID: 16556651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]